A life sciences-focused venture capital investor based in the US is actively seeking new investment opportunities. In addition, the firm recently closed on a new fund through its specialized funds business unit that invests in companies in Asia. The firm generally supports companies with lead assets that can reach high-value inflection points in 3–4 years and will consider opportunities in the U.S., Canada, Europe, Singapore, Hong Kong, and China.
The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. It is therapeutic area agnostic, though it has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers later-stage opportunities, particularly those that have received market approval with early revenue.
The firm does not have any specific requirements for management teams. It is an active investor and seeks a director or observer position on portfolio company boards.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment